Integer (NYSE:ITGR) Releases FY 2024 Earnings Guidance

Integer (NYSE:ITGR) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 5.010-5.430 for the period, compared to the consensus estimate of 5.310. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Integer also updated its FY24 guidance to $5.01-5.43 EPS.

Analyst Ratings Changes

Several brokerages recently commented on ITGR. CL King began coverage on Integer in a report on Thursday, March 14th. They set a buy rating and a $137.00 target price on the stock. Benchmark reaffirmed a buy rating and issued a $130.00 price target on shares of Integer in a report on Friday. KeyCorp upped their price target on Integer from $123.00 to $139.00 and gave the company an overweight rating in a report on Tuesday, April 9th. Finally, Bank of America raised Integer from a neutral rating to a buy rating and upped their price target for the company from $105.00 to $135.00 in a report on Monday, April 15th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Integer currently has a consensus rating of Moderate Buy and an average price target of $120.50.

Integer Stock Down 1.4 %

Shares of Integer stock traded down $1.57 on Friday, hitting $109.58. 604,251 shares of the company traded hands, compared to its average volume of 492,104. The company has a 50-day moving average price of $113.11 and a 200 day moving average price of $99.92. The company has a quick ratio of 1.71, a current ratio of 3.32 and a debt-to-equity ratio of 0.76. Integer has a 12-month low of $69.40 and a 12-month high of $123.99. The company has a market cap of $3.67 billion, a PE ratio of 37.92, a PEG ratio of 1.52 and a beta of 1.10.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million during the quarter, compared to analysts’ expectations of $412.78 million. Integer had a net margin of 6.01% and a return on equity of 11.25%. Integer’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.87 earnings per share. Sell-side analysts predict that Integer will post 5.27 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.